Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,715Revenue (TTM) $M9,674Net Margin (%)-24.9Altman Z-Score0.1
Enterprise Value $M35,502EPS (TTM) $-6.9Operating Margin %-5.8Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.1Pre-tax Margin (%)-25.1Higher ROA y-yN
Price/Book1.210-y EBITDA Growth Rate %23.8Quick Ratio1.1Cash flow > EarningsY
Price/Sales0.45-y EBITDA Growth Rate %36.3Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow2.1y-y EBITDA Growth Rate %-43.8ROA % (ttm)-5.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-49.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M348ROIC % (ttm)-1.2Gross Margin Increase y-yN

Gurus Latest Trades with VRX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VRX is held by these investors:



VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
DE SCHUTTER RICHARD UDirector 2017-03-15Buy10,000$10.8-1.11view
ValueAct Capital Master Fund, 2017-03-14Buy3,000,000$10.82-1.29view
Herendeen PaulEVP and CFO 2017-03-14Buy24,000$10.72-0.37view
Pershing Square Capital ManageDirector 2017-03-13Sell18,114,432$11-2.91view
Ross Thomas W. Sr.Director 2016-12-14Buy5,000$14.73-27.49view
Pershing Square Capital ManageDirector 2016-12-12Sell3,476,690$14.85-28.08view
KARABELAS ARGERIS NDirector 2016-08-11Buy4,000$24.65-56.67view
Ross Thomas W. Sr.Director 2016-06-13Buy4,000$24.4-56.23view
PAPA JOSEPH CCHAIRMAN & CEO 2016-06-10Buy202,000$24.48-56.37view
Pearson J. MichaelCEO 2015-11-05Sell1,297,399$78.48-86.39view

Press Releases about VRX :

Quarterly/Annual Reports about VRX:

News about vrx:

Articles On GuruFocus.com
Francis Chou Comments on Valeant Mar 24 2017 
Chou Opportunity Fund 4th Quarter Message to Shareholders Mar 24 2017 
Bill Ackman Finally Pukes: Beware of False Narratives Mar 25 2017 
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
TransDigm: Cheap but No Thanks Mar 21 2017 
Stocks Decline to Their 3-Year Lows Mar 19 2017 
Valeant - It's Not a Game of Chess Part II Mar 20 2017 
Did Ackman Make the Right Decision to Sell Valeant? Mar 17 2017 
Valeant: It's Not a Game of Chess Part I Mar 16 2017 
Bill Ackman Has Had Enough Precipitous Declines for One Stock, Sells Valeant Mar 14 2017 

More From Other Websites
Behind the Bill Ackman Controversies Mar 28 2017
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive... Mar 28 2017
Former Valeant CEO Files Suit Against the Company Mar 28 2017
Valeant Ex-CEO Pearson Sues Drugmaker Over Withheld Shares Mar 27 2017
Former Valeant CEO sues company over unmade compensation -WSJ Mar 27 2017
[$$] Valeant Former CEO Sues Company Over Unmade Payments Mar 27 2017
TransDigm: The End is Nigh? Mar 27 2017
Drug Manufacturers Continue to be Plagued by Pricing Concerns: Today's Research Reports on Valeant... Mar 27 2017
Vyzulta May Be a Potent Therapy for Glaucoma in the Future Mar 27 2017
Francis Chou Comments on Valeant Mar 24 2017
Chou Opportunity Fund 4th Quarter Message to Shareholders Mar 24 2017
Bausch & Lomb Continues to be Key Growth Driver for Valeant Mar 24 2017
Valeant’s Diversified Products Revenue May Drop in 2017 Mar 24 2017
Valeant Pharmaceuticals is Developing its Sales Force Mar 24 2017
A Safer Way to Play Valeant and Community Health Mar 23 2017
Valeant CEO Compensation Revealed, Shares Climb Mar 23 2017
Siliq May be a Strong Growth Driver for Valeant in 2017 Mar 23 2017
Bill Ackman Is Back at the Sohn Investment Conference This Year Mar 23 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)